688117 Stock Overview
Engages in the research and development, production, sale, and export of peptide drugs.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 5/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
ChengDu ShengNuo Biotec Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥23.33 |
52 Week High | CN¥35.38 |
52 Week Low | CN¥16.46 |
Beta | 0.59 |
11 Month Change | -2.99% |
3 Month Change | -23.61% |
1 Year Change | -16.56% |
33 Year Change | -29.94% |
5 Year Change | n/a |
Change since IPO | -50.14% |
Recent News & Updates
Recent updates
Shareholder Returns
688117 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -4.9% | 1.0% | -1.4% |
1Y | -16.6% | -15.1% | -18.4% |
Return vs Industry: 688117 underperformed the CN Pharmaceuticals industry which returned -15.1% over the past year.
Return vs Market: 688117 exceeded the CN Market which returned -18.4% over the past year.
Price Volatility
688117 volatility | |
---|---|
688117 Average Weekly Movement | 6.2% |
Pharmaceuticals Industry Average Movement | 5.7% |
Market Average Movement | 6.6% |
10% most volatile stocks in CN Market | 10.0% |
10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 688117's share price has been volatile over the past 3 months.
Volatility Over Time: 688117's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 1,128 | Yongjun Wen | www.snbiopharm.com |
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company produces polypeptide APIs, tablets of solid preparation, bottles of freeze-dried powder injections, small-volume injections, pre-filled injections, and card type injections.
ChengDu ShengNuo Biotec Co.,Ltd. Fundamentals Summary
688117 fundamental statistics | |
---|---|
Market cap | CN¥2.61b |
Earnings (TTM) | CN¥72.78m |
Revenue (TTM) | CN¥457.56m |
35.9x
P/E Ratio5.7x
P/S RatioIs 688117 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688117 income statement (TTM) | |
---|---|
Revenue | CN¥457.56m |
Cost of Revenue | CN¥172.73m |
Gross Profit | CN¥284.84m |
Other Expenses | CN¥212.06m |
Earnings | CN¥72.78m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 31, 2024
Earnings per share (EPS) | 0.65 |
Gross Margin | 62.25% |
Net Profit Margin | 15.91% |
Debt/Equity Ratio | 32.0% |
How did 688117 perform over the long term?
See historical performance and comparison